PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 7, 2024New England Journal of Medicine192 citations

Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk

View Full Paper
BBBrian A. BergmarkNMNicholas MarstonTPThomas A Prohaska

Key Points

Key points are not available for this paper at this time.

Abstract

Reducing the levels of triglycerides and triglyceride-rich lipoproteins remains an unmet clinical need. Olezarsen is an antisense oligonucleotide targeting messenger RNA for apolipoprotein C-III (APOC3), a genetically validated target for triglyceride lowering.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Bergmark et al. (2024) studied this question.

synapsesocial.com/papers/68e700f4b6db64358767b7c6https://doi.org/10.1056/nejmoa2402309
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A Null Mutation in Human APOC3 Confers a Favorable Plasma Lipid Profile and Apparent Cardioprotection2008 · 697 citations
  2. 2Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk2021 · 211 citations
  3. 3Hypertriglyceridemia-Associated Pancreatitis: New Concepts and Potential Mechanisms2023 · 49 citations
  4. 4Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk2022 · 741 citations
  5. 5Association of Rare and Common Variation in the Lipoprotein Lipase Gene With Coronary Artery Disease2017 · 205 citations